Gene therapy for glioblestome multiforme: In vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir

Journal of Molecular Medicine

Volumn 75, Issue 4, 1997, Pages 300-304

  Stockhammer, G ^b   Brotchi, J ^c   Leblanc, R ^d   Bernstein, M ^f   Schackert, G ^h   Weber, F ⁱ   Ostertag, C ^j   Mulder, N H ^k   Mellstedt, H ^l   Seiler, R ^m   Yonekawa, Y ⁿ   Twerdy, K ^b   Kostron, H ^b   De Witte, O ^c   Lambermont, M ^c   Velu, T ^c   Laneuville, P ^e   Villemure, J G ^d   Rutka, J T ^g   Warnke, P ^j   Laseur, M ^k   Mooij, J J A ^k   Boethius J ^l   Mariani, L ^m   Meyer, M ^m   Brandli C ⁿ   Frei, K ⁿ   Konu D ⁿ   Gianella Borradori, A ^a   more..

^a Sandoz Pharma Ltd   (Switzerland)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c ERASME HOSPITAL   (Belgium)

^d MCGILL UNIVERSITY   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^j Neurozentrum   (Germany)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^m UNIVERSITY OF BERN   (Switzerland)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR; ANTIMETABOLITE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; CLINICAL PROTOCOL; ENZYMOLOGY; GENE VECTOR; GENETICS; METHODOLOGY;

ANTIMETABOLITES; CLINICAL PROTOCOLS; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 0031110567     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050116     Document Type: Article

References (32)

1. Radhakrishnan K, Bohnen NI, Kurland LT (1994) Epidemiology of brain tumors. In: Morantz RA, Walsh JA (eds) Brain tumors, a comprehensive text. Marcel Dekker, New York, pp 1-18
2. Salcman M (1990) Epidemiology and factors affecting survival. In: Apuzzo MLJ (ed) Malignant cerebral glioma. American Association of Neurological Surgeons, Park Ridge, pp 95-110
3. Werner MH, Phuphanich S, Lyman GH (1995) The increasing of malignant gliomas and primaray central nervous system lymphoma in the elderly. Cancer 76:1634-1642
4. Black P (1991) Brain tumors. N Engl J Med 324:1471-1476
5. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, MacDonald DR, Caincross JG (1994) A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiation Oncol Biol Phys 29:835-839
6. Färkkilä M, Jääskeläinen J, Kallio M, Blomstedt G, Raininko R, Virkkunen P, Paetau A, Sarelin H, Mäntylä M (1994) Randomsied, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70:138-141
7. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D (1994) EORTC Brain Tumor Group. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44:1479-1483
8. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNY, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int Radiat Oncol Biol Phys 18:321
9. Levin VA, Wara WM, Davis RL, Silver P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB (1986) NCOG protocol 6G91: Seven drug chemotherapy and irradiation for patients with glioblastoma multiforme. Cancer Treat Rep 70:739
10. Phillips TL, Levin VA, Ahn DK, Gutin PH, Davis RL, Wilson CB, Prados MD, Wara WM, Flam MS (1991) Evaluation of bromodeoxyuridine in glioblastoma multiforme - a Northern California Cancer Center phase II study. Int J Radiat Oncol Biol Phys 21:709
11. Ammirati M, Galicich JH, Arbit E, Liao Y (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607-614
12. Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traisch D, Brada M (1994) Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer 30A:1809-1815
13. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46:5276-5281
14. Plautz G, Nabel EG, Nabel GJ (1991) Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biologist 3:709-715
15. Borrelli E, Heyman R, Hsi M, Evans RM (1988) Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 85:7572-7576
16. Ezzedine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO (1991) Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex thymidine kinase gene. New Biologist 3:608-614
17. Moolten FL, Wells JM (1990) Curability of tumors bearing herpes thymidine kinase genes transferred by tretroviral vectors. J Natl Cancer Inst 82:297-300
18. Miller AD, Rosman G (1989) Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 980-990
19. Culver KW, Ram Z, Wallbridge S, Ishii, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral-producer cells for treatment of experimental brain tumors. Science 256:1550-1552
20. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53:83-88
21. Roszman T, Elliott L, Brooks W (1991) Modulation of T-cell function by gliomas. Immunol Today 12:370-374
22. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A (1989) Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of TGF-β2. J Immunol 143:3222-3229
23. Couldwell WT, Dore-Duffy P, Apuzzo MLJ, Antel JP, (1991) Malignant glioma modulation of immune function: relative contribution of different soluble factors. J Neuroimmunol 33:89-96
24. Ram Z, Culver KW, Walbridge S, Frank JA, Blaese RM, Oldfield EH (1993) Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg 79: 400-407
25. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN (1993) The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274-5283
26. Chen C-Y, Chang Y-N, Ryan P, Linscott M, McGarrity GJ, Chiang YL (1995) Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated dytotoxicitz and the "bystander effect." Hum Gene Ther 6:1467-1576
27. Bi WL, Parysek LM, Warnick R, Stambrook PJ (1993) In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy. Hum. Gene Ther 4:725-731
28. Colombo BM, Benedetti S, Ottolenghi S, Mora M, Pollo B, Poli G, Finocchiaro G (1995) The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 6:763-772
29. Samejima Y, Meruelo D (1995) "bystander killing" induces apoptosis and is inhibited by forskolin. Gene Ther 2:50-58
30. Oldfield EH, Ram Z, Culver KW, Blaese RM, De Vromm HL, Anderson WF (1993) Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4:39-69
31. Raffel C, Culver K, Kohn D, Nelson M, Siegel S, Gillis F, Link CJ, Villablance JG, Anderson WF (1994) Gene therapy for the treatment of recurrent pediatric malignant astocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 5:863-890
32. Kun LE, Gajjar A, Muhlbauer M, Heideman RL, Sanford R, Brenner M, Walter A, Langston J, Jenkins J, Facchini S (1995) Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-GITk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial malignant brain tumors. Hum Gene Ther 6:1231-1255